[Breast myoepithelioma. Report of a new case and review of literature]

Breast myoepithelioma is rare. A case is reported of a 71 year old femal. The tumor was clinically, radiologically and macroscopically demarcated. Diagnosis was based on histological and immunohistochemical studies. At the time of diagnosis the tumor was composed of myoepithelial cells with few cellular atypias and a low mitotic activity. Tumor cells expressed vimentin, actin, 5100 protein and cytokeratin. No local or distant metastases were found. The patient had been treated initially with a large excision of tumor. Local recurrences detected 1 year after initial syrgery and showed a similar morphology and immunoreactivity with higher mitotic activity. Mastectomy with axillary dissection was performed. No recurrences and no distant metastases detected 2 years later. Myoepithelial tumors generally considered as benign or low- grad lesion can give rise to a wide range of clinical evolution

[Multiple lymphomatous polyposis of the gastrointestinal tract a Tunisian case]

Multiple lymphomatous polyposis is a distinctive primary gastrointestinal lymphoma which endoscopical, histopathological et immunophenotypical characteristics are well known. This lymphoma is rare and its prognosis is bad because of frequency of stage IV patients. We report the case of a 75-yearold male patient with multiple lymphomatous polyposis affecting the rectum, the colon and the stomach associated with an involvement of lymphadenopathies, bone marrow and liver. Treatment by chemotherapy was ineffective and patient dead after 3 sessions of CEOP protocol

Chimiotherapie adjuvante apres chirurgie dans les carcinomes colo-rectaux non metastatiques [resultats de 2 ans. propos de 52 cas]

Purpose: Adjuvant 5-FU based chemotherapy is actually the recommended adjuvant post- operative treatment for stages B2 and C colo-rectal cancers. We report our experience and analyze the therapeutic preliminary results. patients and methods: from December 1989 to august 1996, we collect 52 patients [25 M/27 F] with surgically resected stages B2 [14 pts] and C [38 pts] carcinoma of the colon [39 pts] or rectum [13 pts]. The potients receive adjuvant chemotherapy with 5Flurouracil- levamisole for 1 year or 5Fluoroouracil-Folinic acid for 6 cycles. mean age is 46.7 years [16 to 77] and average delay to diagnosis 6.5 months. we use the Funlevamisole protocol [1 year duration] for 19 patients which 58% receive the totaliy of treatment, 5FU alone [6 cycles] has been used for 7 patients who receive a mean number of 5.2 cycels with a compliance of 64% the resting 31 patients receive the FU-Fol protocal [6 cycles] with a total of 158 cycles administered representing a mean number of 5.2 cycles/ patient with a compliance of 64% Secondary side-effects are essentially digestive represented by diarrhea and/ or abdominal pain or less frequently neutropenia or mucositis. With a median follow-up of respectively 25.8 months [2 to 102], 2 and 3 year actuarial global survival for the whole population is 60 and 30%. According to Dukes stage the survival is respectively 78 and 40% for stages B2 versus 63 and 30% for stages C. the group treated with SFU-Levamisole treatment have a 83 and 57% 2 and 3 year actuarial global survival versus 80 and 33% for the group treated with SFU-Folinic acid- Despite a shorter median follow-up we observe a positive impact of adjuvant chemotheragy on the survival of B2 and C treated patients. However many of our patients have been operated with bulky and/or perfored or infected tumors, factors that reduce the chances of a complete resection